

Matthias Schwenkglenks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1061102/publications.pdf>

Version: 2024-02-01

275
papers

10,753
citations

47006

47
h-index

42399

92
g-index

282
all docs

282
docs citations

282
times ranked

15492
citing authors

#	ARTICLE	IF	CITATIONS
1	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1-5.	6.0	15
2	Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland. <i>European Journal of Health Economics</i> , 2022, 23, 837-846.	2.8	13
3	Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. <i>European Journal of Health Economics</i> , 2022, 23, 807-821.	2.8	9
4	Early mobilisation and rehabilitation in Swiss intensive care units: a cross-sectional survey. <i>Swiss Medical Weekly</i> , 2022, 152, w30125.	1.6	2
5	Silent brain infarcts impact on cognitive function in atrial fibrillation. <i>European Heart Journal</i> , 2022, 43, 2127-2135.	2.2	50
6	Long-term risk of adverse outcomes according to atrial fibrillation type. <i>Scientific Reports</i> , 2022, 12, 2208.	3.3	5
7	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e585-e593.	5.8	26
8	Number of comorbidities and their impact on perioperative outcome and costs – a single centre cohort study. , 2022, 152, w30135.		4
9	Investigational medicinal products, related costs and hospital pharmacy services for investigator-initiated trials: A mixed-methods study. <i>PLoS ONE</i> , 2022, 17, e0264427.	2.5	1
10	Monitoring strategies for clinical intervention studies. <i>The Cochrane Library</i> , 2022, 2022, MR000051.	2.8	5
11	Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, , 1.	3.3	1
12	Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study. <i>PLoS ONE</i> , 2022, 17, e0265507.	2.5	6
13	Small Area Variation of Adherence to Clinical Recommendations: An Example from Switzerland. <i>Health Services Research and Managerial Epidemiology</i> , 2022, 9, 233339282210977.	0.9	0
14	Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis. <i>PLoS Medicine</i> , 2022, 19, e1003980.	8.4	21
15	Association of Different Restriction Levels With COVID-19-Related Distress and Mental Health in Somatic Inpatients: A Secondary Analysis of Swiss General Hospital Data. <i>Frontiers in Psychiatry</i> , 2022, 13, 872116.	2.6	0
16	Scoping review and characteristics of publicly available checklists for assessing clinical trial feasibility. <i>BMC Medical Research Methodology</i> , 2022, 22, 142.	3.1	5
17	A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols. <i>Journal of Clinical Epidemiology</i> , 2022, , .	5.0	1
18	Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIRIT Recommendations in Switzerland, Canada and Germany (ASPIRE-SCAGE). <i>BMJ Open</i> , 2022, 12, e053417.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease. <i>Pharmacoeconomics</i> , 2022, 40, 791-806.	3.3	4
20	Meta-research: Using shared data to provide practical solutions for current research challenges. , 2022, 4, 32-34.		0
21	The Admit-AF risk score: A clinical risk score for predicting hospital admissions in patients with atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 624-630.	1.8	3
22	Association of psychosocial factors with all-cause hospitalizations in patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2021, 44, 51-57.	1.8	5
23	A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 70-78.	5.0	5
24	Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study. <i>BMC Public Health</i> , 2021, 21, 23.	2.9	2
25	Systematic early versus late mobilization or standard early mobilization in mechanically ventilated adult ICU patients: systematic review and meta-analysis. <i>Critical Care</i> , 2021, 25, 16.	5.8	54
26	Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review. <i>Journal of Cancer Survivorship</i> , 2021, 15, 961-975.	2.9	15
27	Blood Pressure and Brain Lesions in Patients With Atrial Fibrillation. <i>Hypertension</i> , 2021, 77, 662-671.	2.7	8
28	Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 931-940.	3.8	6
29	Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. <i>Swiss Medical Weekly</i> , 2021, 151, w20464.	1.6	6
30	Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. <i>JAMA Network Open</i> , 2021, 4, e210380.	5.9	8
31	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 512-519.	0.7	7
32	Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 340-349.	5.0	7
33	Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1546-1556.	1.6	6
34	The INSPIRE Population Survey: development, dissemination and respondent characteristics. <i>BMC Medical Research Methodology</i> , 2021, 21, 131.	3.1	5
35	Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management. <i>JAMA Network Open</i> , 2021, 4, e2111847.	5.9	4
36	Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial. <i>BMC Family Practice</i> , 2021, 22, 123.	2.9	12

#	ARTICLE	IF	CITATIONS
37	Surgical procedures in inpatient versus outpatient settings and its potential impact on follow-up costs. Health Policy, 2021, 125, 1351-1358.	3.0	3
38	Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. Journal of Clinical Pharmacology, 2021, 61, 1406-1414.	2.0	9
39	A qualitative study to investigate Swiss hospital personnel's perceived importance of and experiences with patient's mental-somatic multimorbidities. BMC Psychiatry, 2021, 21, 349.	2.6	5
40	Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial. BMJ, The, 2021, 374, n1585.	6.0	84
41	Utilisation patterns and costs of lipid-lowering drugs in Switzerland 2013-2019. , 2021, 151, w30018.		3
42	Productivity losses due to influenza and influenza-like illness in Switzerland: results of the Swiss Sentinel Surveillance Network in a non-pandemic era. , 2021, 151, .		3
43	Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion. Healthcare (Switzerland), 2021, 9, 1419.	2.0	8
44	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials, 2021, 22, 724.	1.6	9
45	Reliability of Trial Information Across Registries for Trials With Multiple Registrations. JAMA Network Open, 2021, 4, e2128898.	5.9	12
46	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. BMJ Open, 2021, 11, e045239.	1.9	1
47	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013700.	2.8	7
48	Barriers and Facilitating Factors for Conducting Systematic Evidence Assessments in Academic Clinical Trials. JAMA Network Open, 2021, 4, e2136577.	5.9	7
49	Cross-sectional study on the prevalence of influenza and pneumococcal vaccination and its association with health conditions and risk factors among hospitalized multimorbid older patients. PLoS ONE, 2021, 16, e0260112.	2.5	0
50	Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials, 2021, 22, 844.	1.6	20
51	Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data. Journal of Crohn's and Colitis, 2020, 14, 490-500.	1.3	12
52	A scoping review shows that several nonvalidated budget planning tools for randomized trials are available. Journal of Clinical Epidemiology, 2020, 117, 9-19.	5.0	5
53	Trial Forge Guidance 2: how to decide if a further Study Within A Trial (SWAT) is needed. Trials, 2020, 21, 33.	1.6	29
54	Physical Activity Interventions for Primary Prevention in Adults: A Systematic Review of Randomized Controlled Trial-Based Economic Evaluations. Sports Medicine, 2020, 50, 731-750.	6.5	10

#	ARTICLE	IF	CITATIONS
55	Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data. <i>Vaccine</i> , 2020, 38, 1551-1558.	3.8	13
56	A factor score reflecting cognitive functioning in patients from the Swiss Atrial Fibrillation Cohort Study (Swiss-AF). <i>PLoS ONE</i> , 2020, 15, e0240167.	2.5	5
57	“Break the Chains 2015” community-based HIV prevention campaign for men who have sex with men in Switzerland: non-randomised evaluation and cost analysis. <i>BMJ Open</i> , 2020, 10, e032459.	1.9	1
58	Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 317.	2.4	19
59	Degree of regional variation and effects of health insurance-related factors on the utilization of 24 diverse healthcare services - a cross-sectional study. <i>BMC Health Services Research</i> , 2020, 20, 1091.	2.2	8
60	Working Through Ethics Review of Big Data Research Projects: An Investigation into the Experiences of Swiss and American Researchers. <i>Journal of Empirical Research on Human Research Ethics</i> , 2020, 15, 339-354.	1.3	11
61	Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. <i>Cmaj</i> , 2020, 192, E901-E906.	2.0	271
62	Exploring geographic variation of and influencing factors for utilization of four diabetes management measures in Swiss population using claims data. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001059.	2.8	3
63	Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. <i>BMJ Open</i> , 2020, 10, e034565.	1.9	0
64	Impact of a short version of the CONSORT checklist for peer reviewers to improve the reporting of randomised controlled trials published in biomedical journals: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035114.	1.9	21
65	Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT) – rationale and design for an international collaborative study. <i>Trials</i> , 2020, 21, 731.	1.6	10
66	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	4.6	21
67	Introduction to statistical simulations in health research. <i>BMJ Open</i> , 2020, 10, e039921.	1.9	24
68	Going beyond the mean: economic benefits of myocardial infarction secondary prevention. <i>BMC Health Services Research</i> , 2020, 20, 1125.	2.2	1
69	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Network Open</i> , 2020, 3, e2024406.	5.9	53
70	Use of selective serotonin reuptake inhibitors, other antidepressant medication, and risk of cataract: a case-control study based on Swiss claims data. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1329-1335.	1.9	2
71	Insights into the protective effects of influenza vaccination: More hospitalizations but lower follow-up mortality during the 2014/15 influenza season in a Swiss cohort. <i>Vaccine</i> , 2020, 38, 5187-5193.	3.8	2
72	Symptoms and quality of life in patients with coexistent atrial fibrillation and atrial flutter. <i>IJC Heart and Vasculature</i> , 2020, 29, 100556.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Design, analysis and reporting of multi-arm trials and strategies to address multiple testing. International Journal of Epidemiology, 2020, 49, 968-978.	1.9	5
74	Core components and impact of nurse-led integrated care models for home-dwelling older people: A systematic review and meta-analysis. International Journal of Nursing Studies, 2020, 105, 103552.	5.6	33
75	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	3.8	60
76	Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. Pharmacoeconomics, 2020, 38, 747-764.	3.3	7
77	Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines. PLoS ONE, 2020, 15, e0231409.	2.5	14
78	The fragility of trial results involves more than statistical significance alone. Journal of Clinical Epidemiology, 2020, 124, 34-41.	5.0	20
79	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
80	Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects. Trials, 2020, 21, 896.	1.6	9
81	Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study. Swiss Medical Weekly, 2020, 150, w20318.	1.6	13
82	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2019, 68, 827-833.	5.8	7
83	A guidance was developed to identify participants with missing outcome data in randomized controlled trials. Journal of Clinical Epidemiology, 2019, 115, 55-63.	5.0	8
84	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. Journal of Clinical Epidemiology, 2019, 114, 49-59.	5.0	20
85	Functional aging in health and heart failure: the COMLETE Study. BMC Cardiovascular Disorders, 2019, 19, 180.	1.7	30
86	Incidence and Predictors of Atrial Fibrillation Progression. Journal of the American Heart Association, 2019, 8, e012554.	3.7	41
87	Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis. Pharmacoeconomics, 2019, 37, 435-446.	3.3	5
88	Risk of Hospital Admissions in Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 1332-1343.	1.7	37
89	Reporting Quality of Journal Abstracts for Surgical Randomized Controlled Trials Before and After the Implementation of the CONSORT Extension for Abstracts. World Journal of Surgery, 2019, 43, 2371-2378.	1.6	17
90	A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. Journal of Clinical Epidemiology, 2019, 113, 159-167.	5.0	19

#	ARTICLE	IF	CITATIONS
91	Economic burden of symptomatic iron deficiency – a survey among Swiss women. BMC Women's Health, 2019, 19, 39.	2.0	7
92	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	2.8	148
93	Current use and costs of electronic health records for clinical trial research: a descriptive study. CMAJ Open, 2019, 7, E23-E32.	2.4	44
94	Therapeutic Options for Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 480.	7.1	67
95	Open access budget tools for the planning of randomised controlled trials: a scoping review. , 2019, , .		0
96	Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open, 2019, 4, e000596.	4.5	4
97	Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland. BMJ Open, 2019, 9, e031325.	1.9	2
98	Optimising Pharmacotherapy In the multimorbid elderly in primary Care™ (OPTICA) to improve medication appropriateness: study protocol of a cluster randomised controlled trial. BMJ Open, 2019, 9, e031080.	1.9	13
99	Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study. Trials, 2019, 20, 800.	1.6	27
100	Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS ONE, 2019, 14, e0226730.	2.5	30
101	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. PLoS ONE, 2019, 14, e0210669.	2.5	10
102	Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis. Heart Rhythm, 2019, 16, 502-510.	0.7	46
103	Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial. Clinical Endocrinology, 2019, 91, 374-382.	2.4	4
104	Physical inactivity caused economic burden depends on regional cultural differences. Scandinavian Journal of Medicine and Science in Sports, 2019, 29, 95-104.	2.9	13
105	Rationale and design of OPTimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open, 2019, 9, e026769.	1.9	36
106	The sensitivity and specificity of the mannitol bronchial challenge test to identify asthma in different populations: a systematic review. Swiss Medical Weekly, 2019, 149, w20100.	1.6	2
107	Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data. Swiss Medical Weekly, 2019, 149, w20126.	1.6	15
108	Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Medical Weekly, 2019, 149, w20170.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Non-Pharmacological Methods and Post-Operative Pain Relief: An Observational Study. <i>Anesthesiology and Pain Medicine</i> , 2019, In Press, e84674.	1.3	8
110	Glucocorticoids and the Risk of Peptic Ulcer Bleeding: Case-Control Analysis Based on Swiss Claims Data. <i>Drug Safety</i> , 2018, 41, 725-730.	3.2	12
111	Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. <i>Journal of Clinical Epidemiology</i> , 2018, 99, 14-23.	5.0	22
112	Reply to Stern et al. <i>Clinical Infectious Diseases</i> , 2018, 67, 1467-1468.	5.8	1
113	Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 1-11.	5.0	77
114	Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 73-83.	5.0	15
115	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 346-354.	5.8	98
116	How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. <i>European Journal of Health Economics</i> , 2018, 19, 1149-1161.	2.8	46
117	Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 95-107.	9.1	337
118	Bariatric surgery among patients with heart failure: a systematic review and meta-analysis. <i>Open Heart</i> , 2018, 5, e000910.	2.3	29
119	Variation of preoperative chest radiography utilization in Switzerland and its influencing factors: a multilevel study with claims data. <i>Scientific Reports</i> , 2018, 8, 17475.	3.3	4
120	Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study. <i>Lung Cancer</i> , 2018, 121, 61-69.	2.0	49
121	Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 555-564.	4.4	41
122	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0201985.	2.5	3
123	A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). <i>Radiotherapy and Oncology</i> , 2018, 129, 257-263.	0.6	10
124	Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight. <i>Swiss Medical Weekly</i> , 2018, 148, w14626.	1.6	19
125	Funding characteristics of randomised clinical trials supported by the Swiss National Science Foundation: a retrospective cohort study. <i>Swiss Medical Weekly</i> , 2018, 148, w14587.	1.6	1
126	Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data. <i>CNS Drugs</i> , 2017, 31, 245-251.	5.9	33

#	ARTICLE	IF	CITATIONS
127	Generating evidence on a risk-based monitoring approach in the academic setting – lessons learned. BMC Medical Research Methodology, 2017, 17, 26.	3.1	14
128	GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist. Journal of Clinical Epidemiology, 2017, 90, 68-75.	5.0	46
129	Herpes zoster vaccine: A health economic evaluation for Switzerland. Human Vaccines and Immunotherapeutics, 2017, 13, 1495-1504.	3.3	13
130	GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale. Journal of Clinical Epidemiology, 2017, 90, 59-67.	5.0	62
131	GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology, 2017, 87, 14-22.	5.0	124
132	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. Journal of Pediatrics, 2017, 184, 209-214.e1.	1.8	23
133	GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence. Journal of Clinical Epidemiology, 2017, 90, 76-83.	5.0	48
134	Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis. HIV Clinical Trials, 2017, 18, 17-27.	2.0	9
135	A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives. Journal of Thrombosis and Thrombolysis, 2017, 44, 494-506.	2.1	5
136	GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process. Journal of Clinical Epidemiology, 2017, 90, 84-91.	5.0	45
137	Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. Journal of Clinical Epidemiology, 2017, 81, 56-63.	5.0	12
138	Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. Journal of Clinical Epidemiology, 2017, 81, 3-12.	5.0	29
139	Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit. Journal of Clinical Epidemiology, 2017, 82, 12-19.	5.0	8
140	The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 468-475.	6.4	52
141	Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study. BMJ Open, 2017, 7, e016216.	1.9	29
142	Association between Health-Related Quality of Life and Medication Adherence in Pulmonary Tuberculosis in South Africa. Frontiers in Pharmacology, 2017, 8, 919.	3.5	19
143	Health-related quality of life in South African patients with pulmonary tuberculosis. PLoS ONE, 2017, 12, e0174605.	2.5	38
144	Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS ONE, 2017, 12, e0176210.	2.5	153

#	ARTICLE	IF	CITATIONS
145	Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study. BMC Cardiovascular Disorders, 2017, 17, 178.	1.7	8
146	Towards the development of a comprehensive framework: Qualitative systematic survey of definitions of clinical research quality. PLoS ONE, 2017, 12, e0180635.	2.5	6
147	Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. Swiss Medical Weekly, 2017, 147, w14467.	1.6	46
148	Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Medical Weekly, 2017, 147, w14533.	1.6	26
149	Insufficient recruitment and premature discontinuation of clinical trials in Switzerland: qualitative study with trialists and other stakeholders. Swiss Medical Weekly, 2017, 147, w14556.	1.6	15
150	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. PLoS Medicine, 2016, 13, e1002046.	8.4	20
151	Premature Discontinuation of Prospective Clinical Studies Approved by a Research Ethics Committee â€“ A Comparison of Randomised and Non-Randomised Studies. PLoS ONE, 2016, 11, e0165605.	2.5	22
152	How to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis â€“ Designing a Prospective Observational Study in South Africa. Frontiers in Pharmacology, 2016, 7, 125.	3.5	18
153	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. Critical Care Medicine, 2016, 44, 130-137.	0.9	28
154	Guideline of guidelines: thromboprophylaxis for urological surgery. BJU International, 2016, 118, 351-358.	2.5	69
155	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. BMJ Open, 2016, 6, e011148.	1.9	13
156	Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart, 2016, 102, 590-596.	2.9	48
157	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	1.9	18
158	Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06). Clinical Colorectal Cancer, 2016, 15, 314-320.e2.	2.3	6
159	A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. Journal of Clinical Epidemiology, 2016, 80, 8-15.	5.0	130
160	Methods for detecting, quantifying, and adjusting for dissemination bias in meta-analysis are described. Journal of Clinical Epidemiology, 2016, 80, 25-33.	5.0	30
161	Statin use and risk of cholecystectomy â€“ A case-control analysis using Swiss claims data. Expert Opinion on Drug Safety, 2016, 15, 1577-1582.	2.4	5
162	Humidification of indoor air for preventing or reducing dryness symptoms or upper respiratory infections in educational settings and at the workplace. The Cochrane Library, 2016, , .	2.8	1

#	ARTICLE	IF	CITATIONS
163	The reporting of studies using routinely collected health data was often insufficient. Journal of Clinical Epidemiology, 2016, 79, 104-111.	5.0	51
164	Colchicine and Prevention of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2016, 316, 1106.	7.4	6
165	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. Journal of Thoracic Oncology, 2016, 11, 1846-1855.	1.1	80
166	Infection biomarkers in primary care patients with acute respiratory tract infections – comparison of Procalcitonin and C-reactive protein. BMC Pulmonary Medicine, 2016, 16, 43.	2.0	25
167	Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis – a systematic review of global literature with focus on South Africa. Health and Quality of Life Outcomes, 2016, 14, 42.	2.4	40
168	Systematic reviews experience major limitations in reporting absolute effects. Journal of Clinical Epidemiology, 2016, 72, 16-26.	5.0	45
169	Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 207-219.	1.4	31
170	Bias in dissemination of clinical research findings: structured OPEN framework of what, who and why, based on literature review and expert consensus. BMJ Open, 2016, 6, e010024.	1.9	16
171	Cochrane corner: early statin therapy in acute coronary syndromes – what is the clinical benefit?. Heart, 2016, 102, 653-654.	2.9	10
172	Nutritional Support and Outcomes in Malnourished Medical Inpatients. JAMA Internal Medicine, 2016, 176, 43.	5.1	129
173	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. Journal of Clinical Epidemiology, 2016, 69, 152-160.	5.0	19
174	A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 567-567.	1.6	3
175	Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Medical Weekly, 2016, 146, w14382.	1.6	6
176	Influence of hospital characteristics on quality of care in patients with community-acquired pneumonia. Swiss Medical Weekly, 2016, 146, w14337.	1.6	1
177	Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons: SAKK 89/09. Oncology, 2015, 88, 18-27.	1.9	10
178	Completion and Publication Rates of Randomized Controlled Trials in Surgery. Annals of Surgery, 2015, 262, 68-73.	4.2	45
179	Somatostatin Receptor – Targeted Radiopeptide Therapy with ⁹⁰ Y-DOTATOC and ¹⁷⁷ Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial. Journal of Nuclear Medicine, 2015, 56, 171-176.	5.0	63
180	Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 1511-1518.	13.7	326

#	ARTICLE	IF	CITATIONS
181	Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes. Circulation: Cardiovascular Genetics, 2015, 8, 82-90.	5.1	277
182	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics, 2015, 33, 179-190.	3.3	22
183	Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care, 2015, 19, 74.	5.8	44
184	Corticosteroid therapy for pneumonia – Author's reply. Lancet, The, 2015, 386, 956.	13.7	2
185	Using lung cancer mortality to indirectly approximate smoking patterns in space. Spatial and Spatio-temporal Epidemiology, 2015, 14-15, 23-31.	1.7	5
186	Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. BMJ Open, 2015, 5, e009368.	1.9	20
187	Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Research and Treatment, 2015, 152, 67-76.	2.5	61
188	Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland. Pharmacoeconomics, 2015, 33, 1311-1324.	3.3	9
189	Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Supportive Care in Cancer, 2015, 23, 525-545.	2.2	63
190	Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0. , 2015, , .		2
191	Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. PLoS ONE, 2015, 10, e0126984.	2.5	36
192	Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients.. Journal of Clinical Oncology, 2015, 33, e12079-e12079.	1.6	0
193	Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 46-55.	1.0	15
194	Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 455.	2.4	27
195	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, The, 2014, 349, g4539-g4539.	6.0	74
196	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. JAMA - Journal of the American Medical Association, 2014, 311, 1045.	7.4	265
197	Cerebrovascular reactivity predicts stroke in high-grade carotid artery disease. Neurology, 2014, 83, 1424-1431.	1.1	128
198	How to write a surgical clinical research protocol: literature review and practical guide. American Journal of Surgery, 2014, 207, 299-312.	1.8	12

#	ARTICLE	IF	CITATIONS
199	<scp>PAIN OUT</scp>: an international acute pain registry supporting clinicians in decision making and in quality improvement activities. Journal of Evaluation in Clinical Practice, 2014, 20, 1090-1098.	1.8	30
200	Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?. Pharmacoeconomics, 2014, 32, 591-599.	3.3	29
201	Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer, 2014, 14, 201.	2.6	20
202	Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09). BMC Cancer, 2014, 14, 306.	2.6	14
203	Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011. BMC Endocrine Disorders, 2014, 14, 44.	2.2	49
204	A users' guide to understanding therapeutic substitutions. Journal of Clinical Epidemiology, 2014, 67, 305-313.	5.0	3
205	Correlates of satisfaction with pain treatment in the acute postoperative period: Results from the international PAIN OUT registry. Pain, 2014, 155, 1401-1411.	4.2	100
206	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ, The, 2014, 349, g4921-g4921.	6.0	5
207	Dissemination Bias in Systematic Reviews of Animal Research: A Systematic Review. PLoS ONE, 2014, 9, e116016.	2.5	22
208	Impact of Body Mass Index on mortality in Swiss hospital patients with ST-elevation myocardial infarction: does an obesity paradox exist?. Swiss Medical Weekly, 2014, 144, w13986.	1.6	16
209	Publication bias in animal research: a systematic review protocol. Systematic Reviews, 2013, 2, 23.	5.3	21
210	Commentaries on "Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections" with a response from the review authors. Evidence-Based Child Health: A Cochrane Review Journal, 2013, 8, 1372-1375.	2.0	1
211	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. International Journal of Cardiology, 2013, 168, 3878-3883.	1.7	30
212	Population access to new vaccines in European countries. Vaccine, 2013, 31, 2862-2867.	3.8	11
213	Patients' Perception of Postoperative Pain Management: Validation of the International Pain Outcomes (IPO) Questionnaire. Journal of Pain, 2013, 14, 1361-1370.	1.4	124
214	External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 2426-2432.	1.3	7
215	A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clinical Nutrition, 2013, 32, 213-223.	5.0	151
216	Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (A±R)CHOP. Hematology, 2013, 18, 26-29.	1.5	3

#	ARTICLE	IF	CITATIONS
217	The Impact of Early PostOperative Pain on Health-Related Quality of Life. Pain Practice, 2013, 13, 515-523.	1.9	43
218	A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 840-846.	1.9	10
219	Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. Geospatial Health, 2013, 7, 219.	0.8	7
220	The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.. Journal of Clinical Oncology, 2013, 31, 1078-1078.	1.6	0
221	Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. Swiss Medical Weekly, 2013, 143, w13771.	1.6	3
222	The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly. Human Vaccines and Immunotherapeutics, 2012, 8, 328-335.	3.3	50
223	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leukemia and Lymphoma, 2012, 53, 982-984.	1.3	5
224	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIRâ€œCHF trial: an analysis for the UK. European Journal of Heart Failure, 2012, 14, 782-790.	7.1	50
225	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
226	Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. International Journal of Cardiology, 2012, 158, 93-100.	1.7	23
227	Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System. Value in Health, 2012, 15, 65-71.	0.3	27
228	Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Medical Research Methodology, 2012, 12, 131.	3.1	33
229	Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart, 2012, 98, 544-551.	2.9	31
230	The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leukemia Research, 2012, 36, 548-553.	0.8	35
231	Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer, 2012, 20, 647-652.	2.2	51
232	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) â€œ A Systematic Review and Individual Patient Data Meta-Analysis. Blood, 2012, 120, 3655-3655.	1.4	1
233	Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisoloneâ€œSâ€œrituximab chemotherapy: results from an observational study. Leukemia and Lymphoma, 2011, 52, 796-803.	1.3	10
234	Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of nonâ€œST-segment elevation acute coronary syndromes. Value in Health, 2011, 14, 24-33.	0.3	17

#	ARTICLE	IF	CITATIONS
235	Vasopressor administration and sepsis: A survey of Canadian intensivists. <i>Journal of Critical Care</i> , 2011, 26, 532.e1-532.e7.	2.2	14
236	Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. <i>Supportive Care in Cancer</i> , 2011, 19, 483-490.	2.2	47
237	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 175-182.	2.8	60
238	Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial. <i>BMC Family Practice</i> , 2011, 12, 12.	2.9	37
239	Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. <i>BMC Cancer</i> , 2011, 11, 131.	2.6	87
240	Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. <i>Leukemia and Lymphoma</i> , 2011, 52, 1133-1136.	1.3	6
241	KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. <i>Clinical Cancer Research</i> , 2011, 17, 6338-6346.	7.0	74
242	Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 497-507.	2.5	31
243	Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. <i>Journal of Hematology and Oncology</i> , 2010, 3, 27.	17.0	12
244	Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 203-210.	4.4	27
245	Higher vs Lower Positive End-Expiratory Pressure in Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 865.	7.4	1,192
246	Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 18-23.	2.8	32
247	Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. <i>BMJ: British Medical Journal</i> , 2009, 338, b92-b92.	2.3	401
248	Agreement of Swiss-Adapted International and European Guidelines for the Assessment of Global Vascular Risk and for Lipid Lowering Interventions. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 249-254.	2.6	5
249	Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). <i>Trials</i> , 2009, 10, 49.	1.6	28
250	Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. <i>British Journal of Haematology</i> , 2009, 144, 677-685.	2.5	89
251	Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. <i>Journal of Infection</i> , 2009, 58, 446-458.	3.3	225
252	Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2009, 45, 1397-1406.	2.8	65

#	ARTICLE	IF	CITATIONS
253	Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens.. Blood, 2009, 114, 107-107.	1.4	3
254	Cost-Effectiveness of Ferric Carboxymaltose Supplementation in Chemotherapy-Induced Anemia Patients Treated with Erythropoiesis-Stimulating Agents.. Blood, 2009, 114, 1372-1372.	1.4	0
255	Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 2008, 16, 1299-1309.	2.2	122
256	Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health, 2008, 8, 272.	2.9	129
257	Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-Dose Melphalan or BEAM Conditioning Chemotherapyâ€”European Blood and Marrow Transplantation Mucositis Advisory Group. Journal of Clinical Oncology, 2008, 26, 1519-1525.	1.6	155
258	Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary Care. Archives of Internal Medicine, 2008, 168, 2000.	3.8	275
259	Cost of 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Versus Cost of Standard Regimens for the Treatment of Relapsed or Refractory Indolent Non-Hodgkinâ€™s Lymphoma in Switzerland.. Blood, 2007, 110, 3320-3320.	1.4	1
260	Shared-decision making in general practice: do patients with respiratory tract infections actually want it?. Swiss Medical Weekly, 2007, 137, 483-5.	1.6	12
261	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 2046.	7.4	146
262	Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine, 2006, 5, 29-33.	1.5	9
263	Cost-Effectiveness of Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarctionâ€”An Analysis of the EPHEUS Study from a Swiss Perspective. Cardiovascular Drugs and Therapy, 2006, 20, 193-204.	2.6	19
264	Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer, 2006, 14, 901-909.	2.2	55
265	Economic efficiency of gatekeeping compared with fee for service plans: a Swiss example. Journal of Epidemiology and Community Health, 2006, 60, 24-30.	3.7	49
266	Communication training and antibiotic use in acute respiratory tract infections. A cluster randomised controlled trial in general practice. Swiss Medical Weekly, 2006, 136, 241-7.	1.6	26
267	Prevalence and influence of diagnostic tests for acute respiratory tract infections in primary care. Swiss Medical Weekly, 2006, 136, 248-53.	1.6	11
268	A model of osteoporosis impact in Switzerland 2000â€”2020. Osteoporosis International, 2005, 16, 659-671.	3.1	52
269	Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Family Practice, 2005, 6, 34.	2.9	48
270	Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). European Heart Journal, 2004, 25, 2195-2203.	2.2	47

#	ARTICLE	IF	CITATIONS
271	Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. International Journal of Public Health, 2004, 49, 51-61.	2.6	19
272	Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials. American Journal of Medicine, 2004, 117, 596-606.	1.5	132
273	Direct medical costs of type 2 diabetes and its complications in Switzerland. European Journal of Public Health, 2004, 14, 3-9.	0.3	51
274	Costs of Asthma in a Cohort of Swiss Adults: Associations with Exacerbation Status and Severity. Value in Health, 2003, 6, 75-83.	0.3	27
275	The economic efficiency of amlodipine in the treatment of coronary atherosclerosis—an analysis based on the PREVENT study. Cardiovascular Drugs and Therapy, 2002, 16, 61-66.	2.6	9